TriSalus Life Sciences, Inc. provided sales guidance for the full year of 2024. For the year, the company expects sales growth to exceed 50%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +1.95% |
|
+1.41% | -31.83% |
Jun. 03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
May. 30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.83% | 156M | |
+15.33% | 122B | |
+19.27% | 113B | |
+18.95% | 26.49B | |
-24.09% | 19.4B | |
-19.03% | 16.24B | |
-20.84% | 15.4B | |
-46.14% | 15.15B | |
+64.33% | 14.93B | |
+4.40% | 13.52B |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.
- TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024